Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Mon, Aug 18

AbbVie’s rumored $1 billion acquisition of Gilgamesh Pharmaceuticals has amplified attention on the psychedelic therapeutics sector. Stocks of companies like Cybin, Mind Medicine, and GH Research have surged, driven by investor excitement over the promise of psychedelics in treating mental health disorders.

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules designed to promote neuroplasticity without psychoactive effects. This path represents a major leap forward in making psychedelic-like benefits practical, scalable, and clinically accessible.

Lead Candidate: EB‑003

Platform Advantage: Psybrary™

Patent Strength: Melatonin Receptor Compounds

Why Enveric May Be Overlooked…But Shouldn’t Be

The Bigger Picture: Why This Matters Now

AbbVie’s moves, rumored or actual, adding a psychedelic-leaning company like Gilgamesh to its neuroscience portfolio is a signal that big pharma sees genuine promise here. Recent acquisitions and partnerships in psychiatric drug development confirm the trend.

Yet while the spotlight is fixed on overt psychedelic players, Enveric is methodically building a durable, future-proof platform], one that avoids scheduling hurdles and patient resistance, while maximizing therapeutic potential.

Investors, journalists, and partners should be asking: Could this under-the-radar biotech be the one poised to deliver the next big wave in mental health care?

Discover